Givaudan Net Profit Rises Despite Drop in Sales
By Adria Calatayud
Givaudan reported a rise in net profit for last year, thanks to cost controls that allowed it to increase profitability and offset a drop in sales.
Net profit for 2023 was 893 million Swiss francs ($1.04 billion) compared with CHF856 million a year before, the Swiss supplier of chemicals to the food and cosmetics industries said Thursday.
Sales fell to CHF6.915 billion from CHF7.12 billion, dragged by a decline in the company's taste-and-wellbeing segment, it said. For the fourth quarter alone, sales fell 0.5% to CHF1.65 billion.
Full-year earnings before interest, taxes, depreciation and amortization inched lower to CHF1.47 billion from CHF1.48 billion, but Givaudan's Ebitda margin improved to 21.3% from 20.7%, which it attributed to cost management across the business and a performance-improvement program.
Analysts expected Givaudan's 2023 net profit, Ebitda and sales at CHF842 million, CHF1.47 billion and CHF6.92 billion, respectively, according to consensus estimates provided by the company.
The company said it is on track for its 2025 targets, which include average annual organic sales growth of 4% to 5% over a five-year period.
It intends to propose a dividend of CHF68 a share for 2023, up 1.5% on year.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
January 25, 2024 01:23 ET (06:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks